Why Hologic’s Breast Cancer Index data matter for precision oncology beyond recurrence risk
Hologic’s Breast Cancer Index is changing endocrine therapy decisions. The bigger test is adoption in real-world breast cancer care.
Medical Devices & Diagnostics
Pharma & Biotech
How RenovoRx’s TAMP platform data could reshape intra-arterial drug delivery in pancreatic cancer
RenovoRx’s ASCO 2026 data highlights how targeted gemcitabine delivery could reshape pancreatic cancer treatment strategy. Read more.
Pharma & Biotech
Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer?
Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.
Medical Devices & Diagnostics
Veracyte’s ASCO 2026 data could sharpen the commercial case for genomic cancer diagnostics
Veracyte’s ASCO data could sharpen the case for genomic testing in breast and prostate cancer. Read why adoption still faces hard tests.
Medical Devices & Diagnostics
ClearNote Health targets early pancreatic cancer detection with multi-analyte blood test data
ClearNote Health will present Avantect pancreatic cancer test validation data at ASCO 2026. Find out what it could mean for early detection.
Pharma & Biotech
Can PharmaEssentia turn ropeginterferon into a broader myeloproliferative neoplasm franchise?
PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.
Medical Devices & Diagnostics
Can Inocras’ whole-genome HRD data change how ovarian cancer patients are selected for PARP maintenance?
PARP selection still leaves gaps. Inocras’ WGS-HRD data suggest whole-genome testing may refine ovarian cancer maintenance decisions.
Pharma & Biotech
Genentech’s ASCO 2026 data puts giredestrant at the centre of Roche’s breast cancer strategy
Endocrine therapy is crowded. Genentech needs giredestrant to prove it can shift breast cancer care, not just add another option.
Pharma & Biotech
Can logic-gated CAR T therapies finally crack solid tumors? A2 Biotherapeutics shares early ASCO data
A2 Biotherapeutics shares EVEREST-2 CAR T data at ASCO 2026. Find out what this means for solid tumor therapy and next-gen cell treatments.
Pharma & Biotech
Can Forlong Biotechnology’s FL115 poster at ASCO 2026 move the IL-15 story from scientific promise toward clinical relevance?
Forlong Biotechnology brings FL115 to ASCO 2026 with first-in-human solid tumor data. Read why the IL-15 story could matter beyond the poster.